NFA
TVRD

Nationwide Fund Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Nationwide Fund Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-418
Closed -$206K – 2200
2017
Q3 		$206K Hold
418
– – ﹤0.01% 2628
2017
Q2 		$232K Sell
418
-82
-16% -$52K ﹤0.01% 2569
2017
Q1 		$331K Sell
500
-58
-10% -$31K ﹤0.01% 2369
2016
Q4 		$187K Sell
558
-12
-2% -$3.85K ﹤0.01% 2632
2016
Q3 		$171K Buy
570
+9
+2% +$1.95K ﹤0.01% 2703
2016
Q2 		$97K Sell
561
-11
-2% -$2.4K ﹤0.01% 2928
2016
Q1 		$128K Sell
572
-11
-2% -$3.29K ﹤0.01% 2726
2015
Q4 		$354K Sell
583
-351
-38% -$193K ﹤0.01% 2278
2015
Q3 		$481K Buy
934
+397
+74% +$266K ﹤0.01% 2141
2015
Q2 		$235K Sell
537
-18
-3% -$6.96K ﹤0.01% 2629
2015
Q1 		$201K Sell
555
-108
-16% -$40.9K ﹤0.01% 2689
2014
Q4 		$238K Sell
663
-19
-3% -$6.12K ﹤0.01% 2536
2014
Q3 		$206K Hold
682
– – ﹤0.01% 2670
2014
Q2 		$418K Buy
682
+69
+11% +$37.2K ﹤0.01% 2358
2014
Q1 		$411K Buy
+613
New +$363K ﹤0.01% 2145

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nationwide Fund Advisors's TVRD Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2017, closing a stake of 418 shares — an estimated $206K sold.

Nationwide Fund Advisors first reported a position in TVRD in Q1 2014 and held it in 15 quarters. The position peaked at $481K in Q3 2015. 127 funds tracked by Wall St. Rank hold TVRD as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Tvardi Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 418 Tvardi Therapeutics shares in Q4 2017, an estimated $206K.
  • Nationwide Fund Advisors first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 15 quarters.
  • Nationwide Fund Advisors's Tvardi Therapeutics position peaked at $481K in Q3 2015.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.